Opioids and restless legs syndrome: a double-edged sword
- PMID: 36798984
- PMCID: PMC10071373
- DOI: 10.5664/jcsm.10524
Opioids and restless legs syndrome: a double-edged sword
Conflict of interest statement
John Winkelman receives consultation fees from Emalex, Noctrix, and Disc Medicine, and research support from National Institute of Drug Abuse, the RLS Foundation, and the Baszucki Brain Research Fund.
Comment on
-
Emergence of restless legs syndrome during opioid discontinuation.J Clin Sleep Med. 2023 Apr 1;19(4):741-748. doi: 10.5664/jcsm.10436. J Clin Sleep Med. 2023. PMID: 36692170 Free PMC article.
References
-
- Miranda M , Williams AM , Garcia-Borreguero D . Thomas de Quincey and his restless legs symptoms as depicted in “Confessions of an English Opium-Eater” . Mov Disord. 2010. ; 25 ( 13 ): 2006 – 2009 . - PubMed
-
- Walters AS , Wagner ML , Hening WA , et al. . Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo . Sleep. 1993. ; 16 ( 4 ): 327 – 332 . - PubMed
-
- Trenkwalder C , Beneš H , Grote L , et al. RELOXYN Study Group . Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension . Lancet Neurol. 2013. ; 12 ( 12 ): 1141 – 1150 . - PubMed
-
- Winkelman JW , Purks J , Wipper B . Baseline and 1-year longitudinal data from the National Restless Legs Syndrome Opioid Registry . Sleep. 2021. ; 44 ( 2 ): zsaa183 . - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
